NCT03297125Active, not recruiting
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 26 Sept 2017
- Start date
- 1 Dec 2017
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Glioblastoma
- NCT number
- NCT03297125
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Dec 2017 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of craniectomy or significant skull defect (contraindication to Optune).
Other
- Optune compliance \< 75%; they would be excluded from the final analyses.
- Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).
- Karnofsky Performance Status (KPS) \< 60.
Who the study is looking for
- Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Froedtert Hospital/Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.